Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov;58(11):1467-1477.
doi: 10.1080/02770903.2020.1802747. Epub 2020 Aug 21.

The economic burden of severe asthma in children: a comprehensive study

Gizem Pamuk  1 , Muriel Le Bourgeois  1 , Rola Abou Taam  1 , Jacques de Blic  1   2 , Christophe Delacourt  1   2 , Guillaume Lezmi  1   2
Affiliations

The economic burden of severe asthma in children: a comprehensive study

Gizem Pamuk et al. J Asthma. 2021 Nov.

Abstract

Objective: The economic burden of severe asthma (SA) in children is poorly described. We aimed to determine the healthcare costs of SA in children for the French national health insurance (NHI).

Methods: Children (6-18 years of age) with physician-confirmed diagnoses of SA or non-SA (NSA) were identified. Direct and indirect expenditures related to asthma and associated co-morbidities in the previous six months were determined, based on a physician-guided parental questionnaire and confirmed by medical records. The costs for the French NHI were assessed per child over a six month period.

Results: Data from 74 children, including 48 with SA (22 requiring omalizumab) and 26 with NSA, were analyzed. The global cost of SA was €3,982 per child over a six-month period, including €3,821 direct costs and €161.9 indirect costs. The global cost was €6,716 (4,220) for those requiring omalizumab vs. €1,669 (3,108) for those who did not (p < 0.01). For children with SA, 65% of direct costs were attributed to medication. Among those on omalizumab, such treatment accounted for 93% of medication costs. The global cost was 10 times higher for children with SA than those with NSA (€3,982 (4,422) vs. €363.2 (352.6), p < 0.01), and 20 times higher for children with SA on omalizumab than those with NSA (p < 0.01).

Conclusion: The economic burden of SA in children for the French NHI is substantial and mainly driven by the most severe children requiring biologics.

Keywords: Economics; asthma; pediatrics.

PubMed Disclaimer